[New findings with RAS inhibitors in diabetic nephropathy].
Ito
Sadayoshi
S
D000450:Aldosterone / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D018384:Oxidative Stress; D012083:Renin / Q000502:physiology; D000092502:Renin Inhibitors
D000450:Aldosterone; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D012083:Renin; D000092502:Renin Inhibitors